Technical Analysis for 0RD1 - Camurus AB
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 479.46 | 0.25% | 1.18 |
Earnings due: May 8
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Gapped Down | Weakness | 0.25% | |
NR7 | Range Contraction | -1.40% | |
NR7-2 | Range Contraction | -1.40% | |
Up 3 Days in a Row | Strength | -1.40% | |
Up 4 Days in a Row | Strength | -1.40% | |
Stochastic Buy Signal | Bullish | 0.03% | |
NR7 | Range Contraction | 0.03% |
Alert | Time |
---|---|
Possible NR7 | about 20 hours ago |
Rose Above 10 DMA | about 20 hours ago |
Rose Above Previous Day's High | 1 day ago |
Up 1% | 1 day ago |
10 DMA Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
Camurus AB Description
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) was formerly a subsidiary of Sandberg Development AB.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 596.0 |
52 Week Low | 242.4 |
Average Volume | 27,362 |
200-Day Moving Average | 417.35 |
50-Day Moving Average | 486.43 |
20-Day Moving Average | 494.14 |
10-Day Moving Average | 481.57 |
Average True Range | 14.85 |
RSI (14) | 42.86 |
ADX | 17.88 |
+DI | 19.91 |
-DI | 28.70 |
Chandelier Exit (Long, 3 ATRs) | 485.95 |
Chandelier Exit (Short, 3 ATRs) | 509.55 |
Upper Bollinger Bands | 521.27 |
Lower Bollinger Band | 467.00 |
Percent B (%b) | 0.23 |
BandWidth | 10.98 |
MACD Line | -5.91 |
MACD Signal Line | -3.69 |
MACD Histogram | -2.2283 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 499.81 | ||||
Resistance 3 (R3) | 501.05 | 495.51 | 496.42 | ||
Resistance 2 (R2) | 495.51 | 490.33 | 494.89 | 495.29 | |
Resistance 1 (R1) | 487.48 | 487.12 | 484.71 | 486.24 | 494.15 |
Pivot Point | 481.94 | 481.94 | 480.56 | 481.32 | 481.94 |
Support 1 (S1) | 473.91 | 476.76 | 471.14 | 472.67 | 464.76 |
Support 2 (S2) | 468.37 | 473.56 | 467.75 | 463.63 | |
Support 3 (S3) | 460.35 | 468.37 | 462.50 | ||
Support 4 (S4) | 459.10 |